Streetbeat News

Revenues

AMPS

Altus Power has reaffirmed its fiscal year 2024 operating revenue expectations, projecting a range of $200 million to $222 million, with an estimated average of $214.31 million.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 9:09 pm

GROW

US Global Investors (NASDAQ:GROW) reported a 28.45% decrease in sales for Q3, with $2.59 million compared to $3.62 million in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 9:08 pm

FIGS

FIGS has updated its FY24 net revenues outlook, now expecting a change in the range of -2% to +2%, an improvement from its previous forecast of a mid-single-digit decline to flat revenues. This revision indicates a more optimistic view of the company's revenue trajectory for the fiscal year 2024.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 9:07 pm

CTLP

Cantaloupe projects its FY24 total revenue to be between $270M and $275M, which is slightly below the estimated $274.3M.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 9:06 pm

AMPL

Amplitude has increased its FY24 revenue forecast to $292.5M-$295.5M from the previous range of $291.5M-$294.5M, slightly above the estimated $293.13M. Additionally, the company has adjusted its EPS forecast from $0.06-$0.08 to $0.07-$0.09, aligning with the estimated $0.09.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 9:04 pm

MNTK

Montauk Renewables projects its FY24 Renewable Natural Gas (RNG) revenues to be between $195M and $215M.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 9:04 pm

INGR

Analyst ratings for Ingredion (NYSE:INGR) show mixed sentiments, with recent updates indicating a shift towards a more positive outlook. Over the last quarter, ratings varied, but the latest updates from analysts at BMO Capital, Barclays, and Goldman Sachs have raised their price targets, reflecting an optimistic view on Ingredion's future performance. The average 12-month price target now stands at $128.00, up from $119.00, suggesting a 7.56% increase in expected value. Ingredion's financial performance shows strong net margin and ROE, despite a slight decline in revenue growth and a healthy debt management profile.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 9:01 pm

AMPL

Amplitude forecasts Q2 revenue to be between $71.7M and $72.3M, surpassing the estimated $71.469M. The company anticipates an adjusted EPS of $(0.02) to $(0.01), contrary to the expected $0.01.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 9:01 pm

VCEL

Vericel (NASDAQ:VCEL) has been rated by 4 analysts over the last three months, with all showing a bullish stance. The average 12-month price target for VCEL has been raised to $54.00, up from $51.00, indicating a positive outlook on the company's financial performance and market position. Vericel, a biopharmaceutical company, has shown strong financial indicators such as a 23.35% revenue growth rate, a 19.99% net margin, and a 6.04% ROE, outperforming industry standards.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 9:01 pm

AZTA

Recent analyst ratings on Azenta (NASDAQ:AZTA) show a mix of bullish and indifferent sentiments, with 5 bullish and 2 indifferent ratings. The average 12-month price target is $70.43, down from $72.25, indicating analysts' adjusted expectations. Key analysts from firms like Needham and Evercore ISI Group have adjusted their price targets and ratings, reflecting a nuanced view of Azenta's market position and financial performance. Despite facing revenue challenges and below-average ROE and ROA, Azenta's net margin outperforms industry standards, suggesting effective cost management.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 9:00 pm